Drug Trial Radar · NCT02839200
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Last checked: Nov 19, 2026Latest source record: Apr 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Oct 4, 2016
Primary completion
Apr 12, 2017
Study completion Jun 20, 2017
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Conditions
- Insomnia Disorder
Interventions
ACT-541468 5 mgDrug
Capsule for oral administration containing ACT-541468 at a strength of 5 mg
ACT-541468 10 mgDrug
Capsule for oral administration containing ACT-541468 at a strength of 10 mg
ACT-541468 25 mgDrug
Capsule for oral administration containing ACT-541468 at a strength of 25 mg
ZolpidemDrug
Over-encapsulated zolpidem tablet at a strength of 10 mg
Placebo 1Drug
Placebo capsules matching ACT-541468 capsules
Placebo 2Drug
Placebo capsules matching over-encapsulated zolpidem
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2Time frame: Baseline and Days 1&2
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
Investigator Site
Santa Monica, California
Investigator Site
Upland, California
Investigator Site
Brandon, Florida
Investigator Site
Clearwater, Florida
Investigator Site
Coral Gables, Florida
Investigator Site
DeLand, Florida
Investigator Site
Hollywood, Florida
Investigator Site
Miami, Florida
Investigator Site
Atlanta, Georgia
Investigator Site
Chicago, Illinois
Investigator Site
Indianapolis, Indiana
Investigator Site
Novi, Michigan
Investigator Site
Las Vegas, Nevada
Investigator Site
New York, New York
Investigator Site
Cincinnati, Ohio
Investigator Site
Berlin, Germany
Investigator Site
Berlin, Germany
Investigator Site
Berlin, Germany
Investigator Site
Dresden, Germany
Investigator Site
Hamburg, Germany
Investigator Site
Hamburg, Germany
Investigator Site
Hanover, Germany
Investigator Site
Schwerin, Germany
Investigator Site
Schwerin, Germany
Investigator Site
Budapest, Hungary
Investigator Site
Szeged, Hungary
Investigator Site
Törökbálint, Hungary
Investigator Site
Beersheba, Israel
Investigator Site
Haifa, Israel
Investigator Site
Barcelona, Spain
Investigator Site
Barcelona, Spain
Investigator Site
Madrid, Spain
Investigator Site
Zaragoza, Spain
Investigator Site
Gothenburg, Sweden
Investigator Site
Örebro, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.